287 related articles for article (PubMed ID: 31795143)
61. Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53.
Teufel DP; Freund SM; Bycroft M; Fersht AR
Proc Natl Acad Sci U S A; 2007 Apr; 104(17):7009-14. PubMed ID: 17438265
[TBL] [Abstract][Full Text] [Related]
62. Molecular investigation of the dual inhibition mechanism for targeted P53 regulator MDM2/MDMX inhibitors.
Zhao X; Xiong D; Luo S; Duan L
Phys Chem Chem Phys; 2022 Jul; 24(27):16799-16815. PubMed ID: 35775962
[TBL] [Abstract][Full Text] [Related]
63. Insight into mechanism of small molecule inhibitors of the MDM2-p53 interaction: molecular dynamics simulation and free energy analysis.
Chen J; Wang J; Xu B; Zhu W; Li G
J Mol Graph Model; 2011 Sep; 30():46-53. PubMed ID: 21764342
[TBL] [Abstract][Full Text] [Related]
64. Characterizing the Free-Energy Landscape of MDM2 Protein-Ligand Interactions by Steered Molecular Dynamics Simulations.
Hu G; Xu S; Wang J
Chem Biol Drug Des; 2015 Dec; 86(6):1351-9. PubMed ID: 26032728
[TBL] [Abstract][Full Text] [Related]
65. Design and development of high affinity dual anticancer peptide-inhibitors against p53-MDM2/X interaction.
Rasafar N; Barzegar A; Mehdizadeh Aghdam E
Life Sci; 2020 Mar; 245():117358. PubMed ID: 32001262
[TBL] [Abstract][Full Text] [Related]
66. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.
Lu Y; Nikolovska-Coleska Z; Fang X; Gao W; Shangary S; Qiu S; Qin D; Wang S
J Med Chem; 2006 Jun; 49(13):3759-62. PubMed ID: 16789731
[TBL] [Abstract][Full Text] [Related]
67. Markov models of the apo-MDM2 lid region reveal diffuse yet two-state binding dynamics and receptor poses for computational docking.
Mukherjee S; Pantelopulos GA; Voelz VA
Sci Rep; 2016 Aug; 6():31631. PubMed ID: 27538695
[TBL] [Abstract][Full Text] [Related]
68. Mimicking a p53-MDM2 interaction based on a stable immunoglobulin-like domain scaffold.
Jimenez-Sandoval P; Madrigal-Carrillo EA; Santamaría-Suárez HA; Maturana D; Rentería-González I; Benitez-Cardoza CG; Torres-Larios A; Brieba LG
Proteins; 2018 Jul; 86(7):802-812. PubMed ID: 29696695
[TBL] [Abstract][Full Text] [Related]
69. Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function.
Thomas A; White E
Genes Dev; 1998 Jul; 12(13):1975-85. PubMed ID: 9649502
[TBL] [Abstract][Full Text] [Related]
70. Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.
Gessier F; Kallen J; Jacoby E; Chène P; Stachyra-Valat T; Ruetz S; Jeay S; Holzer P; Masuya K; Furet P
Bioorg Med Chem Lett; 2015 Sep; 25(17):3621-5. PubMed ID: 26141769
[TBL] [Abstract][Full Text] [Related]
71. Real-time surface plasmon resonance monitoring of site-specific phosphorylation of p53 protein and its interaction with MDM2 protein.
Wu L; He Y; Hu Y; Lu H; Cao Z; Yi X; Wang J
Analyst; 2019 Oct; 144(20):6033-6040. PubMed ID: 31502598
[TBL] [Abstract][Full Text] [Related]
72. p53-Mdm2 inhibitors: patent review (2009 - 2010).
Kamal A; Mohammed AA; Shaik TB
Expert Opin Ther Pat; 2012 Feb; 22(2):95-105. PubMed ID: 22316395
[TBL] [Abstract][Full Text] [Related]
73. Small-molecule inhibitors of the p53-MDM2 interaction.
Vu BT; Vassilev L
Curr Top Microbiol Immunol; 2011; 348():151-72. PubMed ID: 21046355
[TBL] [Abstract][Full Text] [Related]
74. Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors.
Xue X; Wei JL; Xu LL; Xi MY; Xu XL; Liu F; Guo XK; Wang L; Zhang XJ; Zhang MY; Lu MC; Sun HP; You QD
J Chem Inf Model; 2013 Oct; 53(10):2715-29. PubMed ID: 24050442
[TBL] [Abstract][Full Text] [Related]
75. Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2.
Dastidar SG; Lane DP; Verma CS
J Am Chem Soc; 2008 Oct; 130(41):13514-5. PubMed ID: 18800837
[TBL] [Abstract][Full Text] [Related]
76. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
[TBL] [Abstract][Full Text] [Related]
77. Dual role of p300 in the regulation of p53 stability.
Kawai H; Nie L; Wiederschain D; Yuan ZM
J Biol Chem; 2001 Dec; 276(49):45928-32. PubMed ID: 11591713
[TBL] [Abstract][Full Text] [Related]
78. Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects.
Fry DC; Graves B; Vassilev LT
Methods Enzymol; 2005; 399():622-33. PubMed ID: 16338385
[TBL] [Abstract][Full Text] [Related]
79. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53.
Zondlo SC; Lee AE; Zondlo NJ
Biochemistry; 2006 Oct; 45(39):11945-57. PubMed ID: 17002294
[TBL] [Abstract][Full Text] [Related]
80. Diarylethene moiety as an enthalpy-entropy switch: photoisomerizable stapled peptides for modulating p53/MDM2 interaction.
Strizhak AV; Babii O; Afonin S; Bakanovich I; Pantelejevs T; Xu W; Fowler E; Eapen R; Sharma K; Platonov MO; Hurmach VV; Itzhaki L; Hyvönen M; Ulrich AS; Spring DR; Komarov IV
Org Biomol Chem; 2020 Jul; 18(28):5359-5369. PubMed ID: 32390036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
